The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Milk Thistle Nomenclature: Why It Matters in Cancer Research and Pharmacokinetic Studies
Open accessAbstract
Extracts of milk thistle have been recognized for centuries as “liver tonics” and are well-known to prevent or reverse hepatotoxicity of reactive drug metabolites or naturally occurring toxins. Milk thistle extracts are now under intense study in the experimental therapeutics of cancer for chemoprevention, treatment, and amelioration of chemotherapy side effects. Precision in nomenclature, however, has lagged behind this progress. The crude commercial product of milk thistle is termed silymarin, a complex of at least 7 flavonolignans and 1 flavonoid that comprises 65% to 80% of milk thistle extract. From silymarin is derived silibinin, a semipurified fraction once thought to be a single compound but now recognized as a 1:1 mixture of 2 diastereoisomers, silybin A and silybin B. The distinction between silymarin and silibinin is not only important to understanding the historical literature, but thorough characterization and use of chemically defined mixtures in preclinical and clinical studies are essential to the progress of these botanical compounds as human therapeutics. As a result, we urge clinicians and preclinical investigators alike to exercise rigor in nomenclature and use pure compounds or precisely defined chemical mixtures in subsequent studies. Herein, we provide a guide to the proper nomenclature and composition of milk thistle extracts and discuss the known pharmacokinetic studies of these botanical medicines. The drug-interaction potential of these extracts appears to be quite low, and in fact, silibinin appears to synergize with the antitumor effects of some commonly used chemotherapeutics. However, some precautions are advised as high-dose, phase II studies are conducted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
Ström, A., Hartman, J., Foster, J. S., Kietz, S., Wimalasena, J., & Gustafsson, J.-Å. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308319100 · Cited by 534
Encyclopedia of Dietary Supplements
(2010) · CRC Press eBooks · doi:10.1201/b14669 · Cited by 380
An, J., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N., & Leitman, D. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100953200 · Cited by 323
Tyagi, A. K., Singh, R. P., Agarwal, C., Chan, D. C. F., & Agarwal, R. (2002) · PubMed · Cited by 323
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Flaig, T. W., Gustafson, D. L., Su, L.-J., Zirrolli, J. A., Crighton, F., Harrison, G. S., Pierson, A. S., Agarwal, R., & Glodé, L. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9019-2 · Cited by 315
Kim, N.-C., Graf, T. N., Sparacino, C. M., Wani, M. C., & Wall, M. E. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b300099k · Cited by 278
Lee, D. Y.-W., & Liu (2003) · Journal of Natural Products · doi:10.1021/np030163b · Cited by 242
Barzaghi, N., Crema, F., Gatti, G., Pifferi, G., & Perucca, E. (1990) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190223 · Cited by 226
Davis-Searles, P. R., Nakanishi, Y., Kim, N.-C., Graf, T. N., Oberlies, N. H., Wani, M. C., Wall, M. E., Agarwal, R., & Kroll, D. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4662 · Cited by 218
Self-citationGURLEY, B., GARDNER, S., HUBBARD, M., WILLIAMS, D., GENTRY, W., CARRIER, J., KHAN, I., EDWARDS, D., & SHAH, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.007 · Cited by 212
Lahiri-Chatterjee, M., Katiyar, S. K., Mohan, R. R., & Agarwal, R. (1999) · PubMed · Cited by 208
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., & Kamataki, T. (1998) · Annals of Oncology · doi:10.1023/a:1008438109725 · Cited by 207
Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts
Hartman, J., Lindberg, K., Morani, A., Inzunza, J., Ström, A., & Gustafsson, J.-A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0017 · Cited by 206
SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES
Sridar, C., Goosen, T. C., Kent, U. M., Williams, J. A., & Hollenberg, P. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.587 · Cited by 192
Singh, R. P., Dhanalakshmi, S., Tyagi, A. K., Chan, D. C. F., Agarwal, C., & Agarwal, R. (2002) · PubMed · Cited by 191
Hoh, C., Boocock, D., Marczylo, T., Singh, R., Berry, D. P., Dennison, A. R., Hemingway, D., Miller, A., West, K., Euden, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2724 · Cited by 166
Venkataramanan, R., Ramachandran, V., Komoroski, B. J., Zhang, S., Schiff, P. L., & Strom, S. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15071-4 · Cited by 156
Inhibitory Effects of Silibinin on Cytochrome P‐450 Enzymes in Human Liver Microsomes
Beckmann‐Knopp, S., Rietbrock, S., Weyhenmeyer, R., Böcker, R. H., Beckurts, K. T. E., Lang, W., Hunz, M., & Fuhr, U. (2000) · Pharmacology & Toxicology · doi:10.1111/j.0901-9928.2000.860602.x · Cited by 136
Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer
Deep, G., & Agarwal, R. (2007) · Integrative Cancer Therapies · doi:10.1177/1534735407301441 · Cited by 128
Zi, X., Zhang, J., Agarwal, R., & Pollak, M. (2000) · PubMed · Cited by 126
Seidlová‐Wuttke, D., Becker, T., Christoffel, V., Jarry, H., & Wuttke, W. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00270-x · Cited by 102
Lee, J. I., Hsu, B. H., Wu, D., & Barrett, J. S. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.03.053 · Cited by 101
Weyhenmeyer, R., Mascher, H. J., & Birkmayer, J. G. D. (1992) · PubMed · Cited by 99
Silymarin: What is in the name …? An appeal for a change of editorial policy
Šimánek, V., Křen, V., Ulrichová, J., Vičar, J., & Cvak, L. (2000) · Hepatology · doi:10.1053/jhep.2000.9770 · Cited by 99
[The chemistry and analysis of silymarin from Silybum marianum Gaertn].
Wagner, H., Diesel, P., & Seitz, M. (1974) · PubMed · Cited by 98
Agarwal, R., Katiyar, S. K., Lundgren, D. W., & Mukhtar, H. (1994) · Carcinogenesis · doi:10.1093/carcin/15.6.1099 · Cited by 97
Dvořák, Z., Kosina, P., Walterová, D., Šimánek, V., Bachleda, P., & Ulrichová, J. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00406-x · Cited by 92
Plíšková, M., Vondráček, J., Křen, V., Gažák, R., Sedmera, P., Walterová, D., Psotová, J., Šimánek, V., & Machala, M. (2005) · Toxicology · doi:10.1016/j.tox.2005.06.020 · Cited by 81
Batch solvent extraction of flavanolignans from milk thistle (Silybum marianum L. Gaertner)
Wallace, S. N., Carrier, D. J., & Clausen, E. C. (2005) · Phytochemical Analysis · doi:10.1002/pca.803 · Cited by 77
Wagner, H., Hörhammer, L., & Münster, R. (1968) · PubMed · Cited by 75
Paine, M. F., & Oberlies, N. H. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.1.67 · Cited by 57
Self-citationStereoselective metabolism of silybin diastereoisomers in the glucuronidation process
Han, Y. H., Lou, H. X., Ren, D., Sun, L. R., Ma, B., & Ji, M. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2003.12.002 · Cited by 47
Kroll, D. J., & Oberlies, N. H. (2003) · Focus on Alternative and Complementary Therapies · doi:10.1211/fact.2003.00303 · Cited by 8
Self-citation
Cited by
Antioxidant Therapy: Current Status and Future Prospects
Firuzi, O., Miri, R., Tavakkoli, M., & Saso, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711803414368 · Cited by 468
Multitargeted therapy of cancer by silymarin
Ramasamy, K., & Agarwal, R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.053 · Cited by 442
Silybin and the liver: From basic research to clinical practice
Loguercio, C. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i18.2288 · Cited by 375
Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges
Elmowafy, M., Shalaby, K., Elkomy, M. H., Alsaidan, O. A., Gomaa, H. A. M., Abdelgawad, M. A., & Mostafa, E. M. (2023) · Polymers · doi:10.3390/polym15051123 · Cited by 332
Natural products as photoprotection
Saewan, N., & Jimtaisong, A. (2015) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.12123 · Cited by 306
Metadata
- Authors
- Kroll, D. J., Shaw, H. S., & Oberlies, N. H.
- Venue
- Integrative Cancer Therapies
- Publisher
- SAGE Publications
- Published
- 2007-06
- Volume
- 6
- Issue
- 2
- Pages
- 110-119
- ISSN
- 1534-7354 (ISSN-L)
- 1552-695X
- OpenAlex
- W2117890432
- Cited by
- 268
- References
- 36
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.